Tectonic Therapeutic Inc
Company Profile
Business description
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Contact
490 Arsenal Way
Suite 210
WatertownMA02472
USAT: +1 339 666-3320
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
51
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.60 | 49.30 | -0.55% |
| CAC 40 | 8,097.06 | 27.82 | -0.34% |
| DAX 40 | 24,037.79 | 192.12 | -0.79% |
| Dow JONES (US) | 48,248.00 | 168.56 | -0.35% |
| FTSE 100 | 9,663.57 | 87.74 | -0.90% |
| HKSE | 25,235.41 | 393.47 | -1.54% |
| NASDAQ | 23,001.32 | 56.10 | -0.24% |
| Nikkei 225 | 49,383.29 | 784.82 | -1.56% |
| NZX 50 Index | 13,424.95 | 16.81 | 0.13% |
| S&P 500 | 6,788.97 | 27.54 | -0.40% |
| S&P/ASX 200 | 8,598.90 | 48.40 | -0.56% |
| SSE Composite Index | 3,824.81 | 43.11 | -1.11% |